HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MCK
McKesson Corporation
MCK's fundamentals are mixed: earnings per share grew 21%, while its operating margin held steady at 1.6%. At 28x earnings, it's trading in line with its usual 26x. Analysts expect earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MCK Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
MCK's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MCK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $654 | -39% |
| Forward | 22x | $1,077 | — |
| Fair | 26x | $1,019 | -5.4% |
| Current | 28x | $1,077 | — |
| Expensive | 31x | $1,206 | +12% |
Historical ranges are pointers, not guarantees.
MCK's PE is in its expensive range at 28x. If earnings grow as analysts expect, today's price would be 22x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MCK Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
MCK has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MCK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $48.95 | +26% |
| Q3 2026 | $38.80 | +21% |
| Q2 2026 | $37.28 | +49% |
| Q1 2026 | $38.38 | +49% |
| Q4 2025 | $34.66 | +59% |
| Q3 2025 | $32.02 | +66% |
| Q2 2025 | $24.97 | +12% |
| Q1 2025 | $25.72 | +15% |
| Q4 2024 | $21.85 | -0.9% |
MCK has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MCK on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
MCK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $111B | +7.6% |
| Q2 2026 | $105.4B | +7.7% |
| Q1 2026 | $96.3B | +6% |
| Q4 2025 | $106.2B | +11% |
| Q3 2025 | $103.2B | +10% |
| Q2 2025 | $97.8B | +23% |
| Q1 2025 | $90.8B | +19% |
| Q4 2024 | $95.3B | +18% |
MCK's revenue has grown year over year every quarter since late 2020: $111B last quarter, up 7.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.4% | +0.1 points |
| Q2 2026 | 1.3% | +0.2 points |
| Q1 2026 | 2.2% | +0.5 points |
| Q4 2025 | 1.5% | +0.3 points |
| Q3 2025 | 1.4% | +0.7 points |
| Q2 2025 | 1.1% | -0.2 points |
| Q1 2025 | 1.8% | +0.2 points |
| Q4 2024 | 1.3% | +0.5 points |
MCK has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MCK on cash flow, with more consistent year-over-year improvement.
MCK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3B | +30% |
| Q2 2026 | -$332M | +$697M |
| Q1 2026 | $3.3B | -56% |
| Q4 2025 | $1.1B | +$3.6B |
| Q3 2025 | $2.3B | +18% |
| Q2 2025 | -$1B | +$457M |
| Q1 2025 | $7.6B | +91% |
| Q4 2024 | -$2.5B | -1630% |
MCK generated $7.1B in free cash flow over the past year, up 12% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MCK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.1% | -2.5M shares |
| 1 year | -6.2% | -7.7M shares |
| 3 years | -13% | -18.1M shares |
| 5 years | -25% | -39.1M shares |
| Available history | -35% | -63.3M shares |
MCK has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $894M |
| Q2 2026 | $2.5B |
| Q1 2026 | $2.7B |
| Q4 2025 | $680M |
| Q3 2025 | $818M |
| Q2 2025 | $581M |
| Q1 2025 | $300M |
| Q4 2024 | $827M |
MCK spent $6.8B buying back its own shares over the past year, up 168% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MCK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.4x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 1.1x | Healthy |
| Q1 2025 | -0.0x | Net Cash |
| Q4 2024 | 1.5x | Healthy |
MCK's net debt is less than a year of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MCK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 76.3 | Overbought |
| Stochastic | 82.8 | Overbought |
MCK's weekly RSI is 76 (overbought) and its Stochastic is 83 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MCK PE vs Healthcare Sector
| Metric | MCK | Sector median | Relative |
|---|---|---|---|
| PE | 28x | 26x | 7.4% above |
| PE % | 67 | 29 | 38 pts above |
MCK is trading at 28x earnings, in line with the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MCK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $980.7 | 9.8% above |
| 20 week MA | $906.6 | 19% above |
| 50 week MA | $865.9 | 24% above |
| 100 week MA | $781.2 | 38% above |
| 200 week MA | $628.8 | 71% above |
MCK has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MCK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.4 | $170.8 | +22% |
| 2021 | $170.8 | $240.8 | +41% |
| 2022 | $240.8 | $383.7 | +59% |
| 2023 | $383.7 | $463.0 | +21% |
| 2024 | $463.0 | $576.6 | +25% |
| 2025 | $576.6 | $828.3 | +44% |
| 2026 YTD | $828.3 | $1,077.1 | +30% |
MCK has the edge over HIMS on returns for 2026, with the stronger performance.